Commissioned by the Andhra Pradesh government as part of its renewable energy drive, the project was awarded to Bondada Engineering.
Company's EBITDA Margin increased to 13.20% compared to 11.98% in the same period of the previous year
Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.
EBITDA grew up by 43% YoY to touch ₹187 crore in Q4 FY25
The company’s operating EBITDA stood at ₹6,378 crore. EBITDA margin in the quarter was 14.2%.
The company’s revenue from operations was at ₹2,694.4 crore, down 11.7% from ₹3,052 crore in Q4 FY24.
They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.
Operating margins expanded sharply to 15.2% in the March quarter compared to 12% a year ago
In the financial year ended 2025, the business added 257 new stores. In the previous comparable period, the business opened 539 stores.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
